Bayer Foundation’s Post

🛎 Special Issue alert..!!!!!! Commence by encouraging the submission of research contributions to "LA PRENSA MEDICA ARGENTINA." Graciela Manzur et al has written that... Dermatitis herpetiformis (DH) or Dühring-Brocq disease is an autoimmune ampoule disease described by Louis Dühring in 1884. It affects both men and women, with a peak of incidence between 20 and 50 years. It is more common in Caucasian people and very rare among African and Asian populations. La Prensa Medica Argentina it is a 110 years old journal backed by a network of esteemed publications and organizations instantaneous open access. We are now accepting contributions for research, review articles, commentary, systematic reviews, and meta-analyses, among other formats. To get your special discount offers submit your articles on or before "24 February 2024" Ariel Pablo López Editor in Chief, Faculty of Pharmacy and Biochemistry, UBA, Buenos Aires, Argentina. #Dermatitisherpetiformis #DühringBrocqdisease #Celiacdisease #Gluten #journal #article #LaPrensaMedica #MedicalJournal #100yearoldjournal #InvitingSubmissions Graciela Manzur writings sounds something different right....? click on the URL to know more about the interesting content: https://shorturl.at/afrLS

🛎 Special Issue alert..!!!!!! Commence by encouraging the submission of research contributions to "LA PRENSA MEDICA ARGENTINA." Graciela Manzur et al has written that... Dermatitis herpetiformis (DH) or Dühring-Brocq disease is an autoimmune ampoule disease described by Louis Dühring in 1884. It affects both men and women, with a peak of incidence between 20 and 50 years. It is more common in Caucasian people and very rare among African and Asian populations. La Prensa Medica Argentina it is a 110 years old journal backed by a network of esteemed publications and organizations instantaneous open access. We are now accepting contributions for research, review articles, commentary, systematic reviews, and meta-analyses, among other formats. To get your special discount offers submit your articles on or before "24 February 2024" Ariel Pablo López Editor in Chief, Faculty of Pharmacy and Biochemistry, UBA, Buenos Aires, Argentina. #Dermatitisherpetiformis #DühringBrocqdisease #Celiacdisease #Gluten #journal #article #LaPrensaMedica #MedicalJournal #100yearoldjournal #InvitingSubmissions Graciela Manzur writings sounds something different right....? click on the URL to know more about the interesting content: https://shorturl.at/afrLS

#ASLM2023 #COVID19 pandemic has been somewhat instrumental in establishing laboratory capacity in Africa @ASLM_News #aslm Roche African Society for Laboratory Medicine (ASLM)

Professor Elil Renganathan's latest article, titled "Transferable Data Exclusivity Vouchers are Not the Solution to the Antimicrobial Drug Development Crisis: A Commentary on the Proposed EU Pharma Regulation", published in BMJ Global Health, a top 5% journal in Health Policy. This article was published in collaboration with esteemed colleagues from: 1. Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Germany 2. Amsterdam Institute for Global Health & Development (AIGHD), and Department of Global Health, Amsterdam University Medical Centers, The Netherlands 3. Clinical and Epidemiological Virology, Institute for the Future, Rega Institute for Medical Research, KU Leuven, Belgium 4. Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal 5. Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Germany 6. Institute for Global Health, University College London (UCL), UK 7. Medicines Law & Policy, Amsterdam, The Netherlands 8. Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Italy 9. Africa Health Research Institute (AHRI), South Africa This article sheds critical light on the European Commission's proposal to use Transferable Data Exclusivity Vouchers (TDEVs) as part of the 2023 EU pharma reform aimed at spurring antimicrobial innovations. Their analysis brings to the forefront the challenges and potential pitfalls of TDEVs, emphasizing the need for a shift towards delinking incentives from drug prices and incorporating a blend of push and pull mechanisms to truly address the AMR crisis. #GlobalHealth #AntimicrobialResistance #AMR #EUpharmaReform #PublicHealth #ResearchImpact #SunwayUniversity #Collaboration #InnovationInHealthcare

C1. Fundamentals of Clinical Research [Arabic] Includes : Course73 Lessons This course provides an overview of the general steps of clinical research, hypothesis types, protocol development, pilot study, ethical considerations in clinical research, data collection methods, bias & errors, and study design. Epidemiological study designs are explained with examples including the cross-sectional study, cohort study, case-control study, diagnostic test accuracy studies, and clinical trials. Negida Research Academy

This May is dedicated to ALS Awareness. Redenlab scientists continue working towards strengthening evidence for tracking treatment response in ALS with pharma and international consortia. Our involvement in ALS natural history studies and an understanding of what matters to regulators can aid further clinical outcomes. ALS is a severe disease affecting brain areas essential for communication and safe eating, with varying motor speech deficits influenced by progression rate, genetic factors, and initial impairment site, and new treatments are being trialed annually. Redenlab's experience in FDA Type C and EMA CHMP meetings can assess the suitability of clinical outcomes for efficacy trials. They understand that not all COAs are equal and that the study phase can influence the appropriateness of different outcomes. At the cutting edge of research for ALS, Redenlab has partnered with the insitutions of the University of Melbourne and The University of Queensland. For more information, please visit https://lnkd.in/giYFYpYa. #Research #Study #Speech #ALS #ALSAwareness

Eravacycline is a novel antibiotic of the tetracycline class with activity against a broad spectrum of clinically significant bacteria, including multi-drug-resistant organisms. In this paper, the authors aimed to assess the in vitro effectiveness of eravacycline to carbapenemase-producing Gram-negative bacilli clinical isolates identified in hospitals in Łódź, Poland. 📝 In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland — Brauncajs, et al. Full text is available 👇 https://lnkd.in/dR3ENj2n #medicine #health #research #science 

Better healthcare starts here: Ottawa’s medical research community welcomes long-awaited wet lab facilities The shortage of wet lab space has forced researchers and biotech startups to leave Ottawa. That’s why uOttawa is stepping up to fill that gap. Slated to open in the first half of 2026, the AMRC will be a hotbed of interdisciplinary innovation focused on research that will improve patient care. “The AMRC will help us attract and retain top talent and take the biotech section in Ottawa to a whole new level,” says sylvain charbonneau, vice-president, research and innovation. This will be a game-changer for researchers like MaryEllen Harper, whose research teams are working on developing treatments for metabolic diseases such as Type 2 diabetes. Read or watch the full story - https://lnkd.in/gcgdeQUX #uOttawa #uOttawaAMRC #BetterHealthcare #Ottawa #MedicalResearch #Biotech

Have you checked our new #researchpaper? Some of EPTRI members have published a new research paper entitled "Innovative research methodologies in the EU regulatory framework: an analysis of EMA qualification procedures from a pediatric perspective" on Frontiers in Medicine. Authors have analyzed the positive qualification opinions of novel methodologies for medicine development published on the European Medicines Agency website between 2008 and 2023 to assess the potential pediatric interest in methodologies qualified as “novel methodologies for medicine development” by the EMA.  More information and the full paper are available here 👇 https://lnkd.in/dPwBXCJH Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) Gianni Benzi ONLUS - Pharmacological Research Foundation UNIAMO Federazione Italiana Malattie Rare Onlus EU Science, Research and Innovation

BHU study on Covaxin had serious methodological flaws as per ICMR: Prataprao Jadhav The ICMR has asked the scientific journal to remove the acknowledgement to it and to retract the paper as conclusions made in the paper are not supported by evidence/data. It is expected that good journals only publish papers where conclusions are supported by the data presented in the paper, the minister said. #Methodological | #Acknowledgement | #Scietificjournal | #datapresented | #Unvaccinatedgroups | #CoronavirusVaccine | #Backgroundrates | #Physician | #Examination | #Clinicalrecords | #Ministerofstate | #Healthnews Read more: